86 citations
,
June 2018 in “Cochrane library” This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.
11 citations
,
May 2010 in “Journal of the South African Veterinary Association” This case report describes how a treatment with mycophenolate mofetil and prednisone may be effective in managing autoimmune subepidermal blistering dermatosis in dogs while allowing for steroid reduction.
1 citations
,
June 2025 in “Asian Journal of Medical Sciences” In this study, MMF plus prednisolone was found to induce remission in 81% of patients with proliferative lupus nephritis, with fewer adverse effects such as alopecia and amenorrhea compared to CYC plus prednisolone, despite similar overall remission rates.
2 citations
,
January 2012 in “PubMed” This study found that mycophenolate mofetil is effective for both induction and maintenance therapy in children with severe lupus nephritis, significantly improving proteinuria and antibody levels, without renal flares during maintenance.
137 citations
,
December 2006 in “Arthritis Research & Therapy” This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.